Tag Archives: Clostridium difficile and Pediatrics

Children with inflammatory bowel diseases (IBD) are particularly vulnerable to infection with Clostridioides difficile (CDI)

Multi-omic Analysis of the Interaction between Clostridioides difficile Infection and Pediatric Inflammatory Bowel Disease

Highlights

  • Multi-omics reveals markers of CDI in pediatric IBD patients
  • Identification of metabolites reveals distinctive features for IBD and CDI
  • Isocaproyltaurine is made by C. difficile and associates with active IBD
  • Identifies biomarkers potentially useful for distinguishing disease processes

Summary

Children with inflammatory bowel diseases (IBD) are particularly vulnerable to infection with Clostridioides difficile (CDI). IBD and IBD + CDI have overlapping symptoms but respond to distinctive treatments, highlighting the need for diagnostic biomarkers. Here, we studied pediatric patients with IBD and IBD + CDI, comparing longitudinal data on the gut microbiome, metabolome, and other measures. The microbiome is dysbiotic and heterogeneous in both disease states, but the metabolome reveals disease-specific patterns. The IBD group shows increased concentrations of markers of inflammation and tissue damage compared with healthy controls, and metabolic changes associate with susceptibility to CDI. In IBD + CDI, we detect both metabolites associated with inflammation/tissue damage and fermentation products produced by C. difficile. The most discriminating metabolite found is isocaproyltaurine, a covalent conjugate of a distinctive C. difficile fermentation product (isocaproate) and an amino acid associated with tissue damage (taurine), which may be useful as a joint marker of the two disease processes.

To be redirected to the article in its entirety, please click on the following link:

https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(20)30423-6

The U.S. FDA Designates Johnson & Johnson’s Cadazolid An Orphan Drug For Treatment of C.diff. Infection in Pediatric Patients

The FDA designates Johnson & Johnson’s

cadazolid an Orphan Drug for the treatment of

Clostridium difficile (C. diff) infection

in pediatric patients.

 

 

Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

Cadazolid is a quinoxolidinone antibiotic being developed by Actelion.

 

 

 

 

Source:

Aug. 9, 2017 7:40 AM ET|About: Johnson & Johnson (JNJ)|By: Douglas W. House, SA News Editor